CG From the
-
Caribou Biosciences’ Co-Founder Talks The Future of Genome Editing
7/12/2023
Caribou Biosciences' Rachel Haurwitz, Ph.D. discusses Pfizer's $25 million equity investment in the company as well as its Cas12a chRDNA genome editing technology.
-
What A Week In CGT: Approvals And Advancements
6/29/2023
The cell and gene therapy sector has had quite a week. From FDA approvals to groundbreaking advancements, the cell and gene therapy space has had good news to share. Here’s what’s gone on in just the last week alone.
-
Decibel Therapeutics’ Gene Therapy Strategies To Restore Hearing And Balance
6/28/2023
Decibel Therapeutics is a Boston-based, clinical-stage biotech dedicated to discovering and developing transformative new medicines for hearing and balance disorders. I caught up with Decibel’s CEO and President, Laurence Reid, Ph.D. to learn more about gene therapy as a modality for the ear, the state of the clinical trial, and more.
-
Considerations For Licensing Platforms From Universities
6/16/2023
Even the best platforms and technologies don’t come out of universities IND-ready. Just ask Coeptis Therapeutics, which recently licensed the novel CAR-T platform, SNAP-CAR, from the University of Pittsburgh. Coeptis’ Dave Mehalick, and Dan Yerace discuss the licensing agreement and the growing pains to expect when preparing a new platform for an IND.
-
3 Questions On Precigen’s Cell Therapy Studies
6/13/2023
Clinical Leader recently touched base with Helen Sabzevari, Ph.D., CEO of Precigen, about the biopharma’s clinical-stage research in the CAR-T therapeutics space. The company currently has six products in its clinical pipeline, including three that use its UltraCAR-T platform.
-
The Outlook For Gene Editing In The U.S.
6/8/2023
Gene editing has evolved over the past several years, and 2023 is positioned be a truly pivotal year. To get a true understanding of the current and near-term outlook for gene editing, I caught up with Mike Lehmicke, Vice President, Science and Industry Affairs, Alliance for Regenerative Medicine (ARM).
-
Inside The ISCT Global Regulators Summit 2023
5/30/2023
The ISCT Global Regulators Summit occurred on May 30, 2023. Immediately following the Summit, I attended a post-event press conference to learn the key highlights of the proceedings. Here's what I learned.
-
The Latest On Cell & Gene Live And Cell & Gene: The Podcast
5/18/2023
April and May have been busy months for Cell & Gene: The Podcast and Cell & Gene Live. In case you missed it, here’s a look at just some of what we’ve covered including computational biology’s impact on gene therapy, the future of exosome science, and best practices for in-house CGT manufacturing.
-
The Potential Of Prime Editing
5/15/2023
Ann L. Lee, Ph.D., Chief Technical Officer at Prime Medicine explains prime editing’s potential to make wholesale changes to DNA at one time.
-
Ocugen’s Modifier Gene Therapy Technology
4/27/2023
Ocugen is the Malvern, PA-based biotech focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines. The company has achieved positive, preliminary data for OCU400, a therapeutic approach utilizing a modifier gene therapy platform with the potential to address significant unmet medical need for patients affected by Retinitis pigmentosa (RP) and Leber Congenital Amaurosis (LCA). I talked to Shankar Musunuri, Chairman of the Board, CEO & Co-founder of Ocugen to learn about next steps in the program.